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Abstract
Cataract is one of the most common and visually debilitating complications of pediatric uveitis. It develops as a
consequence of chronic inflammation and steroid use and is seen most often in juvenile idiopathic arthritis (JIA)-
associated uveitis. Cataract extraction with intraocular lens (IOL) insertion has been carried out with a measure of
success in non-uveitic pediatric eyes, but in cases of uveitis, multiple factors affect the final outcome. Chronic
inflammation and its sequelae such as band keratopathy, posterior synechiae, and cyclitic membranes make surgical
intervention more challenging and outcome less certain. Postoperative complications like increased inflammation,
glaucoma, posterior capsular opacification, retrolental membranes, and hypotony may compromise the visual
outcome. Early refractive correction is imperative in pediatric eyes to prevent amblyopia. The use of contact lenses
and intraocular lenses in pediatric uveitic eyes were fraught with complications in the past. Surgical interventions
such as vitreo-lensectomy followed by contact lens fitting and small incision cataract surgery followed by different
types of intraocular lenses have been utilized, and many reports have been published, albeit in small patient
groups. This review analyzes and discusses the existing literature on intraocular lens implantation in cases of
pediatric uveitic cataract surgery.
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Introduction
It is particularly important to detect inflammation in the
eyes of children because the sequelae not only anatomic-
ally change the eye but also, as in the case of pediatric
uveitic cataract, lead to sensory amblyopia and squint,
reducing the child’s visual potential. Pediatric cataract
extraction in non-uveitic eyes has a set of well-
established pre-, intra-, and postoperative rules that un-
fortunately cannot be applied in uveitic cataracts.
Pediatric uveitis, especially when due to juvenile idio-
pathic arthritis (JIA), has a relentless course. The chal-
lenges include the control of inflammation so as to
reduce anatomical damage, for planning intervention as
soon as possible and to reduce postoperative complica-
tions. Another very important factor to consider for
good visual rehabilitation is best refractive correction.
Various techniques like vitreo-lensectomy followed by
contact lens fitting, aphakic glasses, and phacoemulsifi-
cation with intraocular lens insertion have been tried to
optimize refractive correction of uveitic eyes with mixed
results. To minimize post-surgery inflammatory re-
sponse, small incision cataract surgery with primary or
second-stage intraocular lenses has been studied. Differ-
ent intraocular lens materials have been tried to test bio-
compatibility. In this review, we have detailed the
published studies on the topic and have attempted to
find clarity on the difficult subject of intraocular lens in-
sertion in pediatric uveitic eyes (Table 1).
Inflammation and the pediatric eye
Development of cataract is one of the significant compli-
cations of chronic uveitis [1, 2]. Increased susceptibility
of a uveitic eye to developing cataract has been attrib-
uted in part to a combination of posterior synechiae,
systemic corticosteroid therapy, topical corticosteroid
therapy exceeding three drops a day, and chronic inflam-
mation [3].
Uveitis presenting in children is significantly different
from uveitis in adults in terms of cause as well as
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presentation. The uveitis of childhood is most commonly
seen in patients with JIA who are ANA (antinuclear
antibody) positive with oligoarticular arthritis [2, 4, 5].
Other causes of pediatric uveitis are sarcoidosis, pars pla-
nitis, and infective etiologies such as toxoplasmosis, toxo-
cariasis, and herpetic infections. A significant proportion
is idiopathic [4, 6–8]. Children with JIA–uveitis may re-
main asymptomatic despite active inflammation, and
often, uveitis is detected either during routine screening
or because of complications leading to vision loss such as
cataract. Different study groups have reported inflamma-
tory sequelae such as band keratopathy, posterior
synechiae, cataract, ciliary body inflammation, cyclitic
membranes, and reduced aqueous production leading to
hypotony in the eyes with chronic inflammation [9, 10].
Over time, protocols have been introduced regard-
ing early screening and aggressive medical treatment
of children with uveitis. The American Academy of
Pediatrics, British Society for Pediatric and Adolescent
Rheumatology, and Royal College of Ophthalmologists
have set guidelines for regular screening of JIA patients. It
involves high-risk children being screened every 3 months
including a detailed ophthalmic evaluation [11–13]. This
approach has led to early recognition and better control of
inflammation with consequent reduction of inflammatory
sequelae.
Reduction of vision due to cataract is of greater rele-
vance in younger children because of the associated risk
of amblyopia in this group [9]. Any delay in clearing the
visual axis can lead to sensory amblyopia, affecting the
eventual visual outcome and quality of life of the child.
Unfortunately, results of cataract surgery in children
without uveitis cannot be directly applied to uveitic eyes,
which have the dual problem of inflammatory sequelae
and management of primary cause of inflammation.
Tackling both has a profound impact on the timing of
surgery as well as eventual visual outcome.
Factors resulting in poor prognosis and strategies for
their prevention
The factors to consider before planning cataract surgery
in pediatric uveitic eyes are the following: the etiology of
uveitis, patient age, grade of inflammation, preoperative
visual acuity, current systemic and local therapy, and risk
of amblyopia [8, 14]. Children with JIA–uveitis are likely
to have a more complicated post-surgical course com-
pared with uveitis secondary to other causes. This may
be because of the younger age at presentation, estab-
lished inflammatory ocular sequelae, and severe persist-
ent intraocular inflammation [8, 15, 16]. Probst and
Holland [17] reported that postoperative complications
occur significantly more in children than adults. It is
important to know that patients in their study were
treated only with steroids and no other additional
immunosuppressives.
BenEzra and Cohen [15] studied 10 uveitic postcatar-
act surgery eyes which had undergone intraocular lens
(IOL) insertion, in unilateral or asymmetric bilateral
cases. The surgery had been performed without waiting
for uveitis to completely settle, in order to prevent am-
blyopia, as the patient age range was 3 to 8 years. No
additional systemic steroids were added, and 80 % of
patients underwent a second procedure to treat posterior
capsular opacification. Terrada et al. [6] recommended
intraocular lens insertion as unilateral aphakia led to anis-
eikonia and amblyopia.
Other than the cataract, factors that can block visual
axis or affect preoperative vision are band keratopathy,
glaucoma, optic disc involvement, epiretinal membrane,
and macular edema [8, 15]. Woreta et al. [9] studied
inflammatory sequelae in the eyes with JIA–uveitis and
reported band-shaped keratopathy to be the most com-
mon (32 %) followed by posterior synechiae (28 %),
cataract (22 %), ocular hypertension (15 %), and hypot-
ony (9 %). Epiretinal membrane, optic nerve edema, and
macular edema were found in less than 5 % of the eyes.
These factors may affect the final visual outcome of
these patients. They also observed that 44 % of the eyes
with active intraocular inflammation at time of surgery
were associated with an almost threefold increase in
odds of having postoperative ocular complications.
Cataract surgery causes disruption of blood-aqueous
barrier that persists for several weeks in a non-uveitic
eye [18]. Eyes with preexisting inflammation have a
compromised blood-aqueous barrier, which is respon-
sible for an even greater postoperative disruption of the
barrier, leading to fibrin formation and consequent de-
velopment of inflammatory sequelae. Grajewski et al.
[19] reported an improvement of more than two lines in
visual acuity after cataract surgery and intraocular lens
insertion, in a group of 16 patients. It is significant that
surgery had been done only on quiet eyes after good im-
munosuppression with appropriate topical, systemic ste-
roids, immunosuppressives, and biologicals.
It is important therefore to ensure a two-step process
while planning cataract surgery. Step one is to ensure
that the inflammation is well controlled before attempt-
ing cataract surgery. The mandate is a 3-month
inflammation-free period prior to planning cataract sur-
gery [6, 20]. Step two is to continue control in the post-
operative period for a good surgical outcome [19, 21]. In
recent years, advancement in pharmacotherapy, intro-
duction of biologicals, and intravitreal steroid injections
have greatly improved our ability to control inflamma-
tion in JIA–uveitis and other forms of pediatric uveitis
in a shorter period of time [13, 14, 22]. Hawkins et al. [13]
in their review recommended aggressive preoperative and
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postoperative treatment with topical and systemic ste-
roids, including intravenous methylprednisolone and sys-
temic prednisolone, to achieve bilateral quiet eyes. They
recommended the use of immunosuppressive agents such
as methotrexate and mycophenolate mofetil in pediatric
uveitis for better disease control and as steroid-sparing
agents. Cyclosporin was suggested only as an adjunct
treatment. Biological agents targeting TNF alpha such as
infliximab and adalimumab were recommended, with
good results, in uveitis refractory to standard immunosup-
pressives. Cantarini et al. [22] recommended topical ste-
roids as first-line treatment, adding systemic steroids in
cases of failure to achieve control. They warned against
long-term systemic steroid use in children and recom-
mend immunosuppressives and biologicals in the same
way as Hawkins et al. Grajewski et al. [19] recommended
a perioperative intravitreal injection of triamcinolone
acetonide in addition to a preoperative well-controlled
uveitis for good visual outcomes in JIA–uveitis. Studies
conducted on the use of intravitreal steroid implants
like Retisert (fluocinolone acetonide) and Ozurdex
(dexamethasone) in recalcitrant uveitis in children
found that patients uncontrolled on maximum medical
therapy benefited by intravitreal introduction of these
steroid implants. The eyes needed close monitoring for
the development of cataract and glaucoma [23, 24].
Visual recovery: control of inflammation and refractive
correction
Pediatric uveitic eyes needing cataract removal need to
overcome multiple triggers of inflammation: the primary
cause of uveitis, flare-up from surgical intervention, and
the presence of the IOL. Modifications in surgical tech-
niques and testing different IOL materials for minimum
immunogenicity have been tried to improved surgical
outcome. It is also important to address the challenges
faced during biometry for correct IOL power calculation
in these eyes.
Improvements in surgical techniques
Advances in cataract surgery with smaller incisions and
reduced intraoperative manipulation have greatly con-
tributed to reduced inflammation [6, 8, 19, 25]. In the
late 1990s, Vasavada et al. advocated performing a pri-
mary posterior capsulorhexis with anterior vitrectomy in
children with congenital cataract less than 5 years of age
[26]. It had been found to reduce the incidence of post-
operative retro-IOL membranes and posterior capsular
opacification (PCO) and therefore lead to a better visual
outcome. Since then, the procedure has been used ef-
fectively in surgeries for pediatric uveitic cataract as well
[8, 15, 27, 28]. Some studies have reported postsurgical
development of PCO and retro-IOL membranes despite
this procedure [15, 28], indicating the aggressive nature of
inflammation in uveitic eyes. Grajewski et al. [19] sug-
gested performing a pars plana 25-gauge anterior vitrec-
tomy and posterior capsulotomy after phacoemulsification
and “in-the-bag” IOL, with reduced incidence of PCO and
retrolental membranes.
In situations where the sequelae of inflammation like
cystoid macular edema, ciliary membranes, and macular
traction do not resolve with medical management, per-
forming a complete vitrectomy with manual removal of
the ciliary and intravitreal membranes may assist in re-
lieving associated traction, provided the patient is well
supported with good immunosuppression [29]. Palsson
et al. [30] reported favorable visual results with com-
bined phacoemulsification, IOL, and vitrectomy in
pediatric uveitis but advocated the procedure only for
eyes with vitreous pathologies.
Studies in non-uveitic pediatric cataracts reported less
postoperative inflammation and complications such as
glaucoma when the IOL was placed in the bag [31, 32].
This may be because the lens capsule protects the iris
from persistent chafing by IOL haptics. It is seen to
benefit uveitic eyes in reducing postoperative inflamma-
tion, maybe by decreasing physical contact with uveal
structures [8, 16]. Nihalani et al. [31] have used manual
separation of the two leaflets of the remaining capsule
with a MVR blade for secondary in-the-bag IOL im-
plantation in aphakic non-uveitic pediatric cataract. This
may not always be possible in uveitic eyes where postop-
erative inflammation may lead to fibrosis of the capsule.
Magli et al. [33] suggested that delaying the placement
of IOL by about 1 year after cataract extraction signifi-
cantly reduced secondary glaucoma and retrolental
membranes while maintaining similar visual acuity as
primary IOL placement in JIA–uveitic cataracts. They
suggested a reduced quantum of inflammation as the
reason for the better outcome, but, significantly, visual
acuities were found to be reduced in sulcus-placed IOLs
compared to in-the-bag IOLs. We do not feel that this
approach, requiring two interventions and resulting in a
sulcus-fixated lens, should be recommended as it may
potentially result in UGH syndrome postoperatively.
IOL power calculation
Calculating the IOL power is always a challenge in
pediatric eyes due to the changing axial lengths and anter-
ior chamber depths of growing eyes, especially in children
less than 2 years of age [34]. Children with uveitis, espe-
cially JIA–uveitis, usually require cataract surgery around
9.8 years of age (range 4 to 10 years, mean 6 years) [6]. By
this age, healthy eyes are sufficiently grown for appropriate
IOL measurement. However, in uveitic eyes, there are a
number of factors that interfere with surgery planning
such as band-shaped keratopathy affecting keratometry
readings, posterior synechiae affecting anterior chamber
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depth, and hypotony and epiretinal membranes affecting
axial length measurements. To deal with proper measure-
ment of anterior chamber depth and axial length,
immersion A scan biometry seems to be more reliable
[35]. Partial coherence interferometry is restricted by the
age of the child and density of cataract, especially in uvei-
tic eyes. Anterior segment optical coherence tomography
has now become another tool that can help in the accur-
ate determination of anterior chamber depth, but use is
limited by a child’s age. All current IOL power calculation
formulas have high predictive errors in the shortest eyes.
Postoperative refraction target is still controversial, but
low degrees of hyperopia do not seem to adversely impact
long-term visual acuity in children [34].
Refractive correction: IOL or no IOL?
Removing a cataractous lens results in a large refractive
error that must be corrected for the best visual outcome.
The resulting aniseikonia can result in deep amblyopia,
especially in younger children, if not corrected in time.
Contact lenses have been used to treat aniseikonia after
unilateral cataract surgery. There are many problems
that affect the use of contact lenses to correct vision.
Eyes with JIA–uveitis are often on long-term topical
steroid drops, increasing the chances of developing in-
fective keratitis. Band keratopathy makes contact lens
fitting difficult, leading to early intolerance. BenEzra and
Cohen [15] found that contact lens was poorly tolerated
in their group of patients.
Inserting an intraocular lens (IOL) has been widely ac-
cepted for adult uveitic eyes [36] but remains controver-
sial for pediatric uveitic cataracts. In the early 1990s, the
use of IOL in pediatric uveitic eyes was associated with
significant inflammation, development of intractable
glaucoma, cyclitic membrane, hypotony, and phthisis
[37, 38]. In these eyes, the degree of fibrosis around the
IOL led to cocooning of the IOL in the capsular bag
[17, 38]. In 1993, Foster et al.[38] strongly advocated
against intraocular lens implantation in children. In
retrospect, we can see that these studies did not use sys-
temic immunosuppression to control inflammation.
In the past, surgeons suggested keeping eyes aphakic
for better visual outcomes and lensectomies and vi-
trectomies were procedures of preference in these
eyes [38–40], but all of these earlier reports failed to
control ocular inflammation and systemic immuno-
suppressives were not used.
In 1996, Probst and Holland were the first to report
on IOL implants in patients with JIA–uveitis. Seven pa-
tients (eight eyes) underwent phacoemulsification with
intraocular lens insertion, and two were younger than
10 years. A final visual acuity of 20/40 or better was
achieved in seven of the eight eyes. Postoperative com-
plications were more common in the two youngest
patients, suggesting that intraocular lens implants in
younger patients may have more complications [17].
Notably, only corticosteroids were used for suppression
of inflammation in their cases.
In 2000, Ben Ezra and Cohen [15] examined the
outcomes postcataract surgery with posterior chamber
IOL in five eyes of five children (aged 4–8 years) with
JIA–uveitis. Three eyes had postoperative visual acuity
of 6/240 or less, and complications included posterior
synechiae, macular edema, persistent inflammation,
and glaucoma. We need to highlight again that the
authors had not waited for remission of uveitis before
planning cataract surgery, as their focus was the
treatment of amblyopia. Peri-operatively, all patients
were given retro-orbital methyl prednisolone injections
and an intravenous bolus hydrocortisone injection with
no additional systemic steroids or immunosuppressives
postoperatively. But despite the inflammation, the authors
preferred the use of IOLs to contact lens in unilateral
aphakia postuveitic cataract extraction [15].
Gradually changing attitudes and better postoperative
results were reported in recently published studies and
are attributed to improved medical control of inflamma-
tion, new surgical techniques, and more biocompatible
IOLs [6, 8, 21, 25, 28, 41].
Nemet et al. [16] in a landmark study compared 10 pa-
tients with JIA–uveitis with 8 non-JIA–uveitis patients.
They observed that eyes with JIA–uveitis had more se-
vere manifestations of uveitis, an earlier presentation of
cataract as well as a stormier postsurgical course. They
concluded that if inflammation was well controlled,
small incision surgery and foldable acrylic hydrophobic
IOLs could be well tolerated by these eyes. They also
concluded that with effective medical management of
inflammation, final visual acuity in patients with JIA–
uveitis and of those with other causes of uveitis was
comparable. The authors concluded that IOL implant-
ation should no longer be considered an absolute
contraindication in pediatric uveitis. We need to note
that poor visual outcomes and severe inflammatory
sequelae were seen in eyes with poorly controlled
inflammation.
Quinones et al. [8] studied the visual outcomes in
aphakia and pseudophakia in 34 children (41 eyes)
within the age group from 4 to 17 years, with 27 chil-
dren having JIA-associated uveitis. They reported a 92 %
improvement in visual outcome in eyes with poly-
methyl methacrylate (PMMA) posterior chamber IOLs
(PCIOLs) placed in the bag. The authors noted no
difference in postoperative inflammation between pa-
tients who received an IOL and those who did not. It
is important to note that all eyes had been quiet for
at least 3 months before surgery, and patients had
been given perioperative immunomodulatory therapy.
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Four patients with JIA received an IOL implant—all
four were using methotrexate and received intraocular
steroid treatment intraoperatively. Twenty-three per-
cent of children were less than 6 years of age. All of
these patients were operated on by C. Stephen Foster
who in 1993 recommended against lens implantation
in children with JIA.
Similarly, Sijssens et al. [41] compared the outcomes
of aphakia versus pseudophakia in a group of 29 children
(48 eyes) of JIA-associated uveitis. They noted that
though the major risk factors for visual outcome were
duration of disease, severity at onset, and age at develop-
ment of cataract, there was no difference in development
of ocular complications in PCIOL and aphakia. They
also suggested that with maximum control of inflamma-
tion, IOL implantation was associated with better visual
outcomes and reduced risk of postoperative CME and
glaucoma. They suggested that before surgery, risk of
IOL implantation should be evaluated for individual
eyes. Shallow anterior chamber, hypotonic eyes, age less
than 4 years, and bad outcomes with IOL in fellow eye
were considered a contraindication for IOL use.
IOL material
As the IOL seems to be the major trigger of the intraoc-
ular inflammation in uveitic eyes, various materials have
been tried in the search for the least immunogenic one.
Studies document the use of different IOL materials like
silicone, PMMA, heparin surface-modified PMMA
(HSM-PMMA), and hydrophilic and hydrophobic acrylic
lenses [6, 28, 40, 42, 43].
In 2004, Ganesh et al. [44] reported a higher incidence
of PCO development and inflammatory deposits on
PMMA than acrylic lenses. Terrada et al. [6] reported
good visual results with HSM-PMMA coated IOLs in
children with well-controlled uveitis, within an age
group of 4 to 16 years, followed up for a median of
6 years. They went on to suggest that the new gener-
ation of foldable acrylic hydrophobic lenses are biocom-
patible and may reduce inflammatory response because
of small incision surgery. Lundvall and Zetterstrom [28]
followed up seven children (10 eyes, age range 3.5 to
10 years) postcataract surgery with HSM-PMMA lenses
for 5 years. While ensuring uveitis remained under con-
trol, they noted that visual acuity improved in nine eyes.
They recommended the use of HSM-PMMA lens to cor-
rect aphakia, provided the uveitis was well controlled.
Similarly, Lam et al. in 2003 studied five patients (six
eyes) with well-controlled JIA-associated uveitis who
underwent phacoemulsification with IOL (PMMA and
acrylic). They advocated the use of IOL in eyes with
very good inflammation control, as IOL reduces the
risk of amblyopia, while avoiding compliance issues
with contact lenses and risk of corneal infections.
Though the follow-up period was a median of
43.5 months, the age range was of slightly older chil-
dren from 7 to 12 years [21].
Alio et al., in their study in adult uveitic cataract,
found acrylic IOLs to be associated with least amount of
immediate and delayed inflammation, and HSM-PMMA
and acrylic IOLs had the least incidence of uveitis re-
lapse. Silicone IOLs had the highest rates of opacifica-
tion of the posterior capsule [42]. Papaliodis et al., in
their study comparing four types of IOL materials, re-
ported acrylic IOLs to be superior to HSM-PMMA,
PMMA, and silicone lenses in adult uveitic eyes, when
they evaluated inflammation, posterior capsular opacifi-
cation, visual acuity, and macular oedema [43]. The
Perry review concluded that acrylic and HSM lenses per-
formed better in uveitic eyes. They suggested that a lens
with a sharp optic edge had better visual outcomes in
uveitic eyes because of reduced incidence of PCO [45].
A Cochrane review by Leung et al. on types of intra-
ocular lenses for cataract surgery in uveitis included
four studies with a patient profile of adult uveitic eyes
[42, 46–49]. They concluded that there was uncer-
tainty as to which type of IOL gave best visual and
clinical outcomes in uveitic cataract surgery based on
existing studies and advocated a multicenter inter-
national study. Abela-Formanek [50], while comparing
IOL biocompatibility in 72 uveitic eyes versus 68 control
eyes, suggested that though design and biomaterial of the
IOL was important, meticulously performed surgery and
perioperative management of inflammation could not be
overlooked. They compared foldable hydrophilic acrylic,
hydrophobic acrylic, and silicone lenses and found
hydrophilic acrylic lenses to have good uveal but
worse capsular biocompatibility. Hydrophobic acrylic
had low uveal but better capsular biocompatibility,
and silicone lenses showed more severe anterior cap-
sular contraction. They suggested avoiding round
edged hydrophilic acrylic lenses in uveitic eyes be-
cause of accelerated rate of PCO formation seen. As
all their uveitic patients benefited from the surgery
despite the different foldable IOLs, they suggested a
longer follow-up to have more conclusive results. Van
Gelder et al. [14] in their review for adult uveitis also
suggested optimum management of uveitis, including
scrupulous attention to preoperative and postoperative
inflammation and intraoperative technique for excel-
lent visual outcomes.
Conclusions
Most of the studies conducted so far on this subject are
retrospective, with small groups of patients. The most
important prognostic factors for cataract surgery in the
eyes of pediatric patients with uveitis have been patient
selection and control of intraocular inflammation. All
Phatak et al. Journal of Ophthalmic Inflammation and Infection  (2016) 6:12 Page 6 of 8
eyes that have done well in published reports have been
quiet, well-controlled eyes, with no history of recent
flare-ups. Chronic uveitis has been associated with se-
vere complications and poor visual outcomes. Some-
times, in uveitic eyes, especially patients with JIA–
uveitis, despite the use of maximum immunosuppressive
therapy and biologicals along with local or systemic ste-
roids, the ocular inflammation remains active. This is
the group of patients who have poor visual recovery, se-
vere inflammatory sequelae, and sight-threatening com-
plications if an IOL is inserted.
The existing studies advise against using an IOL in pa-
tients with active uveitis despite maximum medication,
very young children, hypotony, eyes with rubeosis, inde-
terminate cause of uveitis, and when IOL-related com-
plications have developed in the other eye.
The data advises for minimally invasive small incision
cataract surgery with foldable IOL, especially in unilat-
eral cataract, when the uveitis is well controlled and the
patient is well controlled systemically,
So far, we do not have definite answers. The existing
data are not sufficient for us to derive definitive conclu-
sions or recommendations regarding lens implantation
in pediatric uveitis patients. Therefore, multiple factors
have to be taken into consideration before deciding for
or against IOL insertion in pediatric uveitic eyes. There
needs to be a prospective and multicenter study involv-
ing ophthalmologists and rheumatologists to have some
definite answers on this subject. Till then, patients must
be evaluated on a case-by-case basis, using extreme cau-
tion, before the final decision is made.
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